Modeling HIV-1 Infection and Immune Responses Under Drugs of Abuse by Mutua, Jones Mutune
MODELING HIV-1 INFECTION AND IMMUNE RESPONSES
UNDER DRUGS OF ABUSE
A DISSERTATION IN
Mathematics
and
Physics
Presented to the Faculty of the University
of Missouri-Kansas City in partial fulfillment of
the requirements for the degree
DOCTOR OF PHILOSOPHY
by
JONES MUTUNE MUTUA
B.S., University of Eastern Africa, Baraton, Kenya, 2012
M.S., University of Missouri-Kansas City, 2014
Kansas City, Missouri
2018
c© 2018
JONES MUTUNE MUTUA
ALL RIGHTS RESERVED
MODELING HIV-1 INFECTION AND IMMUNE RESPONSES
UNDER DRUGS OF ABUSE
Jones Mutune Mutua, Candidate for the Doctor of Philosophy Degree
University of Missouri-Kansas City, 2018
ABSTRACT
The frequent use of drugs of abuse among HIV infected individuals is a major
concern. Drugs of abuse, such as opiates, have been widely associated with enhanc-
ing HIV replication, accelerating disease progression, and diminishing host-immune
responses. Moreover, opiates such as morphine have also been associated with de-
creasing the viral mutation rate. The rapid replication of HIV may result in increased
production of mutant viruses that can escape detection by the host’s immune system.
This shows that the use of drugs of abuse can make it harder to effectively manage
HIV infections. It is thus important to gain insights into the effects of drugs of abuse
on HIV dynamics. This dissertation presents mathematical models that help inves-
tigate the effects of morphine-altered antibody responses on SIV dynamics, effects
of morphine pharmacodynamics on HIV dynamics, and effects of morphine on HIV-
infections with two viral species. Using our models, we show that in a subpopulation
of SIV infected morphine addicted macaques, the presence of drugs of abuse may
cause significantly diminished antibody responses, resulting in more severe infection
with increased SIV infectivity, a decreased viral clearance rate, increased viral load,
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and higher CD4+ T cell loss. We also show that the infection threshold, the viral
load, and the CD4+ T cell count largely depend on morphine pharmacodynamic
parameters. Magnitudes of the basic reproduction number, and the numerical simu-
lations results of our two viral species model show that the wild type virus dominates
both in the presence of morphine and in the absence of morphine. The presence of
morphine generally results in higher proportion of wild-type virus than mutant virus
thereby resulting into a higher total viral load. Results in this dissertation may be
useful to develop HIV control strategies, such as antibody based vaccines, for drug
abuse groups.
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CHAPTER 1
INTRODUCTION
Human Immunodeficiency Virus (HIV) is a common infectious disease that
has become a major public health challenge in the world. Worldwide over 33 million
people currently live with the virus, while an estimated 1.8 million new infections
and 1 million AIDS-related deaths occur annually [78, 83]. Furthermore, according
to UNAIDS [83], 76.1 million individuals have become infected with HIV with 35
million AIDS-related deaths since the start of the epidemic.
HIV is mostly transmitted through sexual intercourse, contaminated blood
mainly from sharing drug injection equipment such as syringes, and mother-to-child
during pregnancy, childbirth, or breastfeeding. Once the virus (Figure 1) invades
the human body, it can eventually progress to acquired Immunodeficiency Syndrome
(AIDS) stage. HIV also attacks the immune system which is responsible for fighting
infections in the body, hence making it weaker and vulnerable to opportunistic infec-
tions. The major challenge about HIV is that no effective cure for the virus currently
exists. This fact has prompted the emergence of studies which look at ways to control
the virus.
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2Figure 1. HIV virion [94].
Among HIV-infected people, the frequency of use and dependence on drugs of
abuse, such as opiates, is rapidly increasing with drug users constituting a large cohort
within the HIV-infected population [21, 67]. The Centers for Disease Control and
Prevention [10] estimated that in the US 28% of total AIDS cases and 33% of yearly
new HIV cases were associated with the use of drugs of abuse. These statistics reflect
that the use of drugs of abuse drastically exacerbates the public health burden. More
importantly, drug users, once infected with HIV, are at a greater risk of suffering from
higher viral load, rapid disease progression, and higher HIV-associated neurocognitive
disorders (HAND) [28, 71, 92]. It is thus critical to understand how drugs of abuse
affect the viral dynamics within HIV-infected individuals.
One of the effects of drugs of abuse that has been shown in laboratory ex-
periments is the alteration of virus-specific antibody responses [38]. These experi-
ments, utilizing simian immunodeficiency virus (SIV) infection in morphine addicted
macaques, have provided useful insights of antibody responses in the presence of drugs
of abuse. Virus-specific antibodies have the significant role of protecting individuals
against a wide variety of viral infections. These antibodies are known to play a role in
3controlling established HIV infection, and preventing new infections [44, 59]. These
observations indicate that drugs of abuse can impact virus dynamics indirectly by
altering antibody responses.
We note that these experimental studies [37, 38] have utilized constant mor-
phine. However, drugs of abuse are often taken periodically and the concentration of
drugs of abuse changes periodically over time. Thus, the periodic use of these drugs of
abuse can result into periodic changes of virus-specific antibody concentrations in the
body. Therefore, when devising antibody mediated controls, such as with vaccines, it
is important to study how the alteration of antibody responses due to the presence
of drugs of abuse can change various aspects of viral dynamics both in the constant
morphine and periodic morphine cases.
Some previous studies provide key insights into the mechanisms that form
the basis of multiple infections of cells by HIV [18, 34, 40]. In the center of these
multiple infections are virions that have diverse genetic material and may become
resistant to drug therapies, or may escape the host immune responses all together.
This leads to significant barriers to the treatment of HIV by antiviral drugs or to the
development of effective vaccines. The use of drugs of abuse could be attributed to
the virions escaping the immune responses. Experimental studies [70, 80] have shown
that morphine contributes to viral replication and evolution. However, the exact role
morphine plays in virus dynamics with viral evolution remains unclear. It is thus
important to understand the effects of morphine on the viral dynamics of HIV when
multiple viral species, namely wild-type and mutant viruses, are present.
Mathematical modeling of virus dynamics has been useful in understanding
4the interplay of viral dynamics and immune responses [9, 58, 63, 64]. However, limited
study has been done relating to modeling of HIV dynamics and drugs of abuse [82, 88].
Our goal in this dissertation is to provide such mathematical models that offer insights
on the effects of opiates, such as morphine, on viral dynamics of HIV.
In chapter 2, we provide some background of relevant mathematical modeling
of HIV dynamics, and biological concepts for HIV such as the HIV life cycle and the
immune system. We also present some techniques for theoretical analysis used in the
dissertation.
In chapter 3, we develop viral dynamic models that incorporate virus-specific
antibody responses to study the quantitative effects of morphine-altered antibody re-
sponses on SIV infection dynamics over the first 200 days post infection. The models
are parameterized using viral load and virus-specific antibody data from morphine-
addicted macaques infected with a mixture of SIV and SHIV (simian human immun-
odeficiency virus).
In chapter 4, we develop and analyze a model for HIV dynamics under periodic
morphine intake. We conduct an analysis of the non-autonomous model system and
establish the local and global properties of viral dynamics. Furthermore, we discuss
how various aspects of pharmacodynamics of morphine affect the viral dynamics in
HIV-infections.
In chapter 5, we develop and analyze a viral dynamics model with two viral
species under morphine conditioning. We calculate the basic reproduction number
for each virus strain and perform numerical simulations to examine the effects of
morphine on the HIV-infection dynamics in wild-type and mutant virus.
5In chapter 6, we present the conclusions and discussion of the dissertation.
CHAPTER 2
HIV BACKGROUND AND LITERATURE REVIEW
HIV life cycle
An HIV virion requires a cell in order to replicate. The virus targets the
helper T cells, specifically known as CD4+ T cells, which are vital in maintaining a
fully functioning immune system which is responsible for fighting infections [84]. The
CD4+ T cells contain proteins that can bind to foreign substances such as HIV. The
virus starts its process of replication by binding itself to the receptors on the surface
of the CD4+ T cell. The HIV envelope and membrane of the cell then join together
allowing the HIV virion to enter the CD4+ T cell. Since HIV is a retrovirus and
has two strands of RNA, a DNA copy of the RNA is made inside the cell through a
process known as reverse transcription. The viral RNA is converted to DNA in the
CD4+ T cell nucleus. Through the integration process, the converted viral DNA is
carried to the nucleus of the cell and hidden into the DNA of the CD4+ T cell. At
this stage, when the CD4+ T cell makes its proteins, it also makes new HIV proteins.
Through the transcription process, the HIV strands separate and a new strand is
created which gives instructions on making new HIV. As these new strands are made,
each corresponds to a string of proteins. This process continues until the strand is
translated to a virus particle which is able to make new protein. The new immature
(noninfectious) virus particles then assemble on the surface of the cell after which they
bud from the host CD4+ T cell and mature to become infectious utilizing protease
6
7proteins [84]. A schematic diagram of the HIV life cycle is presented in Figure 2.
Figure 2. Schematic diagram of the HIV life cycle [94]
As this process of viral replication continues, the infected individual’s immune
system weakens. The individuals then mainly go through acute and chronic HIV
infections before reaching the AIDS stage, which is the final and most severe of the
HIV infection stages [39, 84]. After the initial HIV infection, individuals experience
symptoms which can be compared to those of a flu infection. At this stage of infection,
the viral load is very high, then after a relatively short period of time the viral load
declines to reach a set point where it can remain for many years. In an effort to control
8the HIV replication process, HIV antiretroviral drugs have been developed. The major
classes of these antiretroviral drugs include fusion inhibitors, reverse transcriptase
inhibitors, integrase inhibitors, and protease inhibitors.
Immune system
The immune system is responsible for preventing the body against infections
as well as removing existing infections. It comprises of cells, tissues, and molecules
which work together to protect the body. There are two types of immunity: innate and
adaptive. Innate immunity acts as the front line defense mechanism which protects
the body from most common infections. Adaptive immunity, on the other hand,
is an immune response that must recognize foreign materials in the body by using
white blood cells commonly known as lymphocytes (T and B cells). The T cells help
eliminate foreign materials that live inside the infected cell of an individual and also
help the B cells to make antibodies. The B cells main activity is the production of
antibodies which help to kill foreign invaders before they can infect an individual’s
cell.
In addition to antibodies playing a major role in controlling HIV infections, the
“killer” T cells, also known as cytotoxic T lymphocytes (CTLs), are also important
HIV immune control T cells. The production of cytokines can limit viral reproduction,
reduce the amount of receptors available on the target cells, and destroy infected cells
directly [49]. As these CTLs are continuously generated, they exert pressure on the
virus which can cause the virus to mutate to a form that can evade the CTLs [15, 68].
Maintaining a well functioning immune system is very important especially in the
fight against HIV, since a dysfunctional one can lead to increased viral loads and/or
9increased disease progression.
Viral dynamics modeling
Many studies on HIV dynamics modeling have been undertaken more than we
can exhaustively review here. Thus in this dissertation, we present a brief summary
of some articles which have focused on within-host HIV dynamics models relating
to immune system, and drugs of abuse. We also highlight some experimental studies
which provide information that has been, and can be, useful in developing new models.
We start by considering the simplest and earliest basic model of viral infection
[32, 93]. This model incorporates the main classes of HIV infection which include
uninfected target cells, T , infected cells, I , and free virus, V (see Figure 3).
Figure 3. Schematic diagram of the basic model of HIV infection.
In this model, target cells are generated at a constant rate λ and die at per
capita rate d . Upon interaction with free virus, the target cells become infected at
10
a rate β . Infected cells die at a per capita rate δ and produce virus at a rate p per
infected cell. Virions are cleared at a per capita rate c . The model is described by
the following set of ordinary differential equations:
dT
dt
= λ− βV T − dT,
dI
dt
= βV T − δI, (2.1)
dV
dt
= pI − cV.
This model was shown to be able to describe the kinetics of acute HIV infection
[61, 64, 65, 75] and has led to the development of the field of study on viral dynamics
[58, 63].
Tomaras et al. [81] extended the basic model (2.1) by considering the effects
of antibodies in enhancing virion clearance, neutralizing virus, and the possibility of
enhancing the rate of infected cell loss. This model provided a description of both
the antibody timing and the viral load dynamics to determine salutary or detrimental
effects of early antibody responses on control of plasma viremia. From this model,
it was observed that the initial B-cell response to the transmitted or founder virus
does not control initial virus levels during the first 40 days of virus infection. An
important question about the effectiveness of these antibodies posed in the study
was whether they could be protective if they are present before infection, or whether
different types of antibodies would need to be used from the development of effective
HIV-1 vaccines and induced prior to infection.
Ciupe [14] developed a mathematical model of multivalent antibody binding.
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This model was used to determine the dynamical interactions between HIV and an-
tibodies as well as to predict conditions under which pre-existing or HIV induced
antibodies contribute to viral protection. The model results show that at the be-
ginning of infection, the total virus largely consists of free virus, and just a few
antibody-virion immune complexes. However, the results show that after about 1
year, less than 1% of the total virus is free and the remaining proportion is in the
form of antibody-virion complexes.
Ciupe et al. [13] presented models which investigate poly-specific and strain-
specific neutralizing antibodies following HIV infection. One of the models described
antibody immune responses following continuous immunization, whereas the other
described antibody responses following natural infection. The numerical results from
these models present a situation where viruses are cleared in the presence of only
poly-specific immune responses and persist when both strain-specific and poly-specific
neutralizing antibodies are present.
Viral RNA can evolve rapidly and can often evade the activities of the host
immune responses and adapt to varying environments [19, 33, 95]. Models have been
developed that account for the evolution of virus during the course of infection. One
of the best ways in which virus evolution has been described is by considering the
dynamics of different virus strains with different traits. Ball et al. [5] developed
a model that extended the basic model of viral dynamics (2.1) and examined the
competition between virus strains within an infected host. The model results showed
that the virus strains were dominant at the beginning and at the late stages of the
infection.
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Alizon and Boldin [3], inspired by Ball et al. [5], developed a model with
multiple target cells. The model results show interesting properties in co-receptor
switching including the initial dominance of virus strains that infect CCR5+ cells, a
late switch in some HIV infections and an associated drop in the number of uninfected
T-cells.
Other studies that have developed models that factor in mutation of virus
include the work by Nowak and Bangham [56] that explored the relationship be-
tween immune responses, viral load and virus diversity. A model which captures the
antigenic escape dynamics was developed by Wodarz and Nowak [20]. Their model
specifically incorporated mutant virus and immune responses, which can include ei-
ther B cells or T cells. This model assumes that each strain-specific response responds
to only one strain.
HIV infections and drugs of abuse
Experimental studies have shown that drugs of abuse constitute to the alter-
ation of virus-specific antibody responses. Here we present a few that have provided
valuable insights on the effects of drugs of abuse on HIV infections. Kumar et al. [38]
presented a study that involved an experiment carried out on six morphine-exposed
and 3 control male Indian rhesus macaques that were intravenously inoculated with
mixture of SIV viruses. They followed these animals for about 56 weeks to determine,
among other things, the binding as well neutralizing antibody levels and cellular im-
mune responses.
Rivera-Amill et al. [70] presented a review study that contributes to the
understanding of how drugs of abuse might influence immune selective pressure to
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variation in different SIV genes. Their work showed that viral evolution is altered in
the setting of drugs of abuse. However, one limitation of this study was that it could
not determine the direct impact of morphine on evolution.
Mathematical modeling of HIV under drugs of abuse is very limited. A most
recent model on HIV dynamics and drugs of abuse is provided by Vaidya et al. [87].
This model consists of two subpopulations of target cells (CD4+ T cells) categorized
based on the level of co-receptor expressions - one with lower susceptibility to infection
(i.e. lower infection rate) due to a low level of co-receptor expression, Tl , and another
with higher susceptibility (i.e. higher infection rate) due to a high level of co-receptor
expression, Th . In addition, the model contains productively infected cells, I , and
free virus, V . The study assumes that target cells are generated at a constant rate
λ and die at per capita rate d . Upon interaction with free virus, target cells, Tl
and Th , become infected at rates βl and βh , respectively. Infected cells die at a per
capita rate δ and produce virus at a rate p per infected cell. Virions are cleared at
per capita rate c . Parameters r and q denote the transition rates from Tl to Th and
from Th to Tl , respectively. The differential equations for this model are
dTl
dt
= λ+ qTh − dTl − rTl − βlV Tl Tl(0) = Tl0,
dTh
dt
= rTl − dTh − βhV Th − qTh Th(0) = Th0,
dI
dt
= βlV Tl + βhV Th − δI I(0) = I0, (2.2)
dV
dt
= pI − cV V (0) = V0.
The model is validated by fitting it to the experimental viral load data [38], and key
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parameters are estimated. This is the first model to have provided SIV viral dynam-
ics parameter estimations in the presence of drugs of abuse. The model parameter
estimations supported the experimental observation [8, 43, 47, 76, 77] that morphine
promotes co-receptor expression in target cells, which can cause increased susceptibil-
ity of these cells to HIV/SIV infection. The study showed higher basic reproduction
number (R0 ) estimates in morphine-dependent animals than in control animals, in-
dicating that morphine may induce additional obstacles for intervention strategies.
The model, however, did not capture immune response effect in viral dynamics and
the reason for this was because the model described the effects of morphine only for
the first 3 months post-infection, when immune responses are largely absent.
A thesis study by Uhl [82], developed a novel mathematical model with two
viral species (wild-type and mutant viruses) and cellular immune responses (CTLs)
that incorporated immune escape and morphine effects. The model simulates the
increase in viral load that results from the use of morphine by introducing terms that
lower the mutation rate of the virus and host’s cellular immune response. The results
from this study shows that the virus population switch, and wild-type dominance, oc-
curs for sufficiently high morphine concentration. The results also show that reduced
cellular immune response results in higher set point viral load.
Data fitting
In fitting the data to a model system of ordinary differential equations (ODEs),
one can estimate some unknown parameters associated with the model. These ODEs
are solved numerically using “ode15s” or “ode45” solvers in MATLAB. Together with
these MATLAB solvers, the optimization functions “fminsearch” and “fmincon” are
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also used. The most common data fitting method used is the least squares method.
In this fitting method, the sum of the square residuals, i.e., the difference between
the model predictions and the corresponding experimental data values, is minimized.
The following formula is used for calculating the sum of the squared residuals:
J =
1
M
M∑
i=1
(y − yi)2 (2.3)
where M represents the total number of data points considered for fitting, and y
and yi represent the values predicted by the model and those given by the experi-
mental data, respectively. Another form of least squares analysis method is known
as non-linear least squares. This method is used to fit a set of k observations with
a model that is non-linear in l unknown parameters (k > l). This fitting method is
made easier by the use of the “lsqcurvefit” solver in MATLAB. For the best model
parameter estimates obtained from the data fitting, a common practice is to find
the confidence intervals (CI), which are computed from n replicates, by bootstrap-
ping the residuals [6, 24] obtained using the formula (2.3). One important aspect of
the bootstrapping process is re-sampling with replacement. That means during this
process, the randomly selected data samples can contain repeated data points.
Generally, in obtaining the confidence interval (CI) of model parameter esti-
mations by bootstrapping method, the following steps are followed. (1) Choose a
sample of m data points. (2) Re-sample the m data points over and over again,
with replacement. (3) Run the simulation of the model and calculate the residual
error between the simulated curve and the data at each data point. (4) Calculate the
standard deviation of the error. This becomes the standard deviation for a normally
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distributed random error term. (5) At each time point of the data, add a randomly
chosen error from step 4 to the simulated curve at that point, and mark it as new
data. (6) Repeat step 2 through 5 n times. (7) Run the model fitting simulations on
each of the n bootstrapped data points, and calculate 95% confidence interval based
off of the results of these simulations.
Model comparison
Akaike’s Information Criterion (AIC) provides a way to compare the quality
of each model, relative to each of the other models being considered. Using the AIC
computed values, a determination is made on which model most adequately describes
reality among the examined ones. The best model is the one that has the lowest AIC
values among all the other models. The following formula is used for calculating the
AIC values [1]:
AIC = M loge
(
J
M
)
+
2M(Np + 1)
M −Np − 2 (2.4)
where J is the sum of squared residuals, M is the number of data points used in
data fitting, and Np is the number of parameters estimated in the fitting.
Comparison of two groups using the p-value
A p-value is a number that lies between 0 and 1. This value helps us make
a determination whether the results obtained in a study are statistically significant
or not. A small p-value (usually < 0.05) indicates that the results being examined
are statistically significant, whereas a large p-value (usually > 0.05) indicates that
there is no statistical significance to the compared results. In MATLAB, one can
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easily calculate the p-values using the t-test commands “[h, p] = ttest2(x, y)” for
two samples with equal means, and “[h, p] = ttest2(x, y, ’Vartype’,’unequal’)” for
two samples of unequal variance. p represents the p-value returned after running the
command, and x and y represent the vectors of the samples being compared. If the
command returns a value of h = 0, this indicates that ttest2 does not reject the null
hypothesis at the default 5% significance level.
The basic reproduction number (R0)
In the within-host modeling, the basic reproduction number, R0 , is defined
as the average number of secondary infections occurring from a single infected cell
among entirely uninfected cells [4, 16]. An important note about the R0 is that it is
a dimensionless number and not a rate, meaning it has no unit. In deriving the basic
reproduction number, the next generation operator method [17, 89] is used. In this
method, a model system described by a set of ordinary differential equations (ODEs)
is considered. From these ODEs, two matrices of partial derivatives are created
by differentiating every equation with respect to every variable. The first matrix,
denoted by F , includes entries of the infectious terms that appear in each differential
equation. The second matrix, denoted by V , includes entries that provide the average
time spent between compartments. If an equation has neither infectious terms nor
transfer terms, then the entries in the respective matrix are zeros. The product of F
and V−1 gives the total new infections. The eigenvalues of the total new infections
matrix (i.e., eigenvalues of FV−1 ) are calculated. The basic reproduction number,
therefore, is the largest of these eigenvalues. Mathematically, this can be summarized
as follows:
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From the ODEs, we introduce matrices F =
[
∂Fi(x0)
∂xj
]
and V =
[
∂Vi(x0)
∂xj
]
where Fi represents the new infections, Vi represents transfer of infection from one
compartment to another, and x0 represents the infection free equilibrium. The basic
reproduction number, R0 , is the dominant eigenvalue of the matrix FV−1 .
CHAPTER 3
MODELING HIV DYNAMICS IN MORPHINE-ALTERED ANTIBODY
RESPONSES
In this chapter, using mathematical models that incorporate virus-specific an-
tibody responses and experimental data from morphine-addicted macaques, we exam-
ine how morphine can alter virus-specific antibody responses affecting the dynamics
of simian immunodeficiency virus infection in macaques. We show that morphine can
significantly diminish virus-specific antibody responses in a sub-population of ani-
mals, hence resulting in reduced virus neutralization, reduced viral clearance, and an
increased CD4+ T cell loss over the first 200 days post infection.
Introduction
The use of drugs of abuse such as opiates among HIV-infected people has been
rapidly increasing. Drug abusers, once infected with HIV, suffer from higher viral
load, rapid disease progression, and higher HIV-associated neurocognitive disorders
(HAND) than non-drug users. Alteration of virus-specific antibody responses due to
drugs of abuse may explain such infection complexity in drug abusers.
Experiments utilizing simian immunodeficiency virus (SIV) infection in mor-
phine addicted macaques have provided useful understanding of antibody responses in
the presence of drugs of abuse [38]. While morphine addicted animals show antibody
responses of relatively smaller magnitude than control animals [38], whether these
differences are significant in noticeably changing viral infection dynamics is not yet
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understood. Experimental evidence and the recent modeling study [87] indicate that
morphine use does not seem to significantly affect immune responses during the first
12 weeks post-infection. However, antibody responses and the effects of morphine on
antibody levels become significantly pronounced over a longer period of time post-
infection [38]. Moreover, careful consideration of the longer-term data obtained from
individual SIV-infected animals indicate that about half of the morphine addicted
animals studied exhibited rapid disease progression resulting in a very short lifespan
[38]. This suggests that as far as the effects of morphine on long-term SIV infection
is concerned, there are two different subpopulations of morphine-addicted animals,
namely, a rapid-progressor morphine group and a slow-progressor morphine group as
categorized in Kumar et al. [38]. Aligned with these different responses of animals
to SIV infection under morphine conditioning, the rapid-progressor morphine group
did not develop detectable antibody responses, whereas the slow-progressor morphine
group and the control group did. Thus, there appears to be a complex relationship
among morphine, antibody responses and virus dynamics that modeling may be able
to reveal.
Experiment and data
Rhesus macaques used for the study were obtained from the Caribbean Re-
search Primate Center and housed in the Animal Resource Center of the University of
Puerto Rico, San Juan. The experimental protocol was approved by the Institutional
Animal Care and Use Committee and the research was performed in accordance with
the Guide for the Care and Use of Laboratory Animals [53].
The data used in this study was obtained from an experiment involving 12 male
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rhesus macaques (Macacamulatta)-six morphine-dependent and six control macaques
[37, 38]. The animals were negative for simian T-cell leukemia virus type 1 and simian
retrovirus. The morphine dependence was established by injecting intramuscularly
increasing doses of morphine (1-5 mg/kg) over a 2-week period. All 12 animals
were infected intravenously with mixture of viruses SHIVKU−1B ,SHIV89−6P , and
SIV17E−Fr . These animals were monitored for a period of 28 weeks, and levels of
circulating CD4+ T cells, viral loads, and virus-specific antibody were measured at
weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 28 post-infection as
described in [37]. The morphine-dependent animals were maintained on morphine
throughout the study period.
Model development
The model developed in this chapter generalizes the viral dynamics model
previously used to describe HIV infection in humans and SIV infection in macaques
[41, 57, 62, 65, 75, 87]. In particular, we extend a previous SIV dynamics model
(2.2) under morphine conditioning [87] by incorporating the effects of virus-specific
antibody responses. The previous study [87] modeled the effects of morphine seen
early in infection, i.e., within 3 months post infection, where immune responses were
largely absent. Here we focus on modeling the effects of morphine for a longer pe-
riod of time, during which virus-specific antibody responses become important. The
schematic diagram of our model is presented in Figure 4.
As in Tomaras et al. [81], we consider three major possible effects of virus-
specific antibodies: reduction in virus infectivity, i.e. virus neutralization, with ef-
ficacy A , enhanced virus clearance due to antibody binding to cell-free virus with
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per capita rate σA(t), and antibody-dependent destruction of infected cells with per
capita rate γA(t). Here, A(t) represents the time course of virus-specific antibody
levels. We model the efficacy of virus neutralization by antibody using the formula
A =
ηA(t)
1+ηA(t)
, whose value lies between 0 and 1 with A = 0 in the absence of antibod-
ies (i.e., A(t) = 0) and A = 1 for extremely high antibody levels (i.e. A(t) → ∞).
η , σ and γ are constants introduced to represent the net effect of antibodies on the
virus dynamics parameters governing viral infection, viral clearance and infected cell
death. Note that η = 0, σ = 0 and γ = 0 represent the model corresponding to the
absence of antibodies [81].
Virus-specific antibody data [38] show that following infection the virus-specific
antibody level remains low, then gradually increases and finally saturates to a max-
imum level (see Figure 5). To capture this trend, we model the antibody response
curve as A(t) = at
n
bn+tn
, where a represents the maximum antibody level, b represents
the time post-infection when the antibody level becomes half of the maximum and n
is a Hill coefficient.
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Figure 4. Schematic diagram of the model. Uninfected CD4+ T cells: Tl and Th ;
infected cells: I ; free virus: V ; virus-specific antibody responses: A ; target cells
generation rate: λ ; death rate of uninfected cells: d ; infection rates: βl and βh ;
infected cells death rate: δ ; virus production rate: p ; clearance rate: c ; transition
rates: r and q from Tl to Th and from Th to Tl , respectively; efficacy of virus
neutralization: A ; enhanced virus clearance rate: σA(t); and destruction of infected
cells rate: γA(t).
The full model we study is described by the following set of equations:
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dTl
dt
= λ+ qTh − dTl − rTl − (1− A)βlV Tl, Tl(0) = Tl0
dTh
dt
= rTl − dTh − qTh − (1− A)βhV Th, Th(0) = Th0
dI
dt
= (1− A)βlV Tl + (1− A)βhV Th − δI − γA(t)I, I(0) = I0 (3.1)
dV
dt
= pI − cV − σA(t)V, V (0) = V0.
where
A(t) =
atn
bn + tn
(3.2)
and
A =
ηA(t)
1 + ηA(t)
(3.3)
Parameter estimation
As discussed in Vaidya et al. [87], we take Th0 = 40, 980/ml , Tl0 = T (0)−Th0
for the control group, and Th0 = 60, 650/ml , Tl0 = T (0)−Th0 for the morphine groups
(both rapid-progressor and slow-progressor) as the initial populations of target cells,
where T (0) is the total number of initial target cells per ml. According to the estimate
of the number of target cells for SIV infection in macaques [85], we take 5% of the
measured CD4 count as the value of T (0). As estimated in Mohri et al. [52] and
Stafford et al. [75], we take 100 days as the average life span of uninfected target cells,
i.e., d = 0.01 per day. Since the animals were initially uninfected, we set I0 = 0 [85].
As estimated previously [87], we take the virus infectivity rates as βl = 5.72× 10−10
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ml/day and βh = 5.72 × 10−8 ml/day. Chen et al. [11] estimated the SIV burst
size in vivo in rhesus macaques as approximately 5 × 104 virions per infected cell.
Because productively infected cells live about 1 day [48], we take the viral production
rate p = 5 × 104 virions per day per infected cell. As estimated by Ramratnam et
al. [66], the virion clearance rate during chronic infection in humans varies between
9.1 per day and 36 per day. Here we use the average c = 23 per day. However, we
recognize that this rate might be higher in macaques [96].
Each macaque was infected intravenously with 2-ml inoculums containing 104
TCID50 of each of SHIVKU−1B , SHIV89−6P , and SIV17E−Fr . The total of 3× 104
TCID50 of viruses comprises at least 3× 105 SIV RNA copies [46]. A macaque, on
average, weighs 1/10 of a human, which approximately gives 1.5 liters of extracellular
water in a macaque. Assuming that the infused virions (RNA copies) are dispersed
into the extracellular water, the initial viral load, V0 , can be estimated as V0 ≈
3× 105/1.5L ≈ 200 viral RNA copies/ml. Thus, we take V0 = 200 copies/ml.
We estimate parameters a , b , and n associated with antibody response curve,
A(t), from the virus-specific antibody data, using the nonlinear least-squares “lsqcurve-
fit” solver in MATLAB. The A(t) curve is then used as a known function in the viral
dynamics model. To estimate other key model parameter values, the system of ordi-
nary differential equations (ODEs) is solved numerically using the “ode15s” solver in
MATLAB. Using the nonlinear least squares regression formula (2.3), the predicted
log10 viral load values are fitted to the corresponding log-transformed viral load data.
For each best-fit parameter estimate, 95% confidence intervals (CI) are provided,
which are computed from 500 replicates, by bootstrapping the residuals [6, 24]. Un-
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less otherwise stated, a two-tailed test with two samples of unequal variance is used
to test for significance of the estimated parameters in this chapter.
Results
Morphine-altered virus-specific antibodies
Using experimental data, we obtained the antibody response curve, A(t), for
each animal from the rapid-progressor morphine group, the slow-progressor morphine
group, and the control group. The estimated values for a , b , and n along with their
median values are given in Table 1. The best-fit curves for each animal are shown
in Figure 5. To highlight the distinction between the groups, we also plotted the
curves for each group corresponding to median values of a , b , and n (Figure 6). As
mentioned earlier, the pattern of antibody response is that initially the antibody level
remains relatively low, then gradually increases and later saturates. Our estimates
show that the maximum antibody level, a , the time post-infection when the antibody
level becomes half of the maximum, b , as well as the Hill coefficient, n , in the rapid-
progressor morphine group are significantly lower (p < 0.05) than the control group
(median a = 1.5 ng/ml, b = 0.3 days, n = 1.99 for the rapid-progressor morphine
group versus the median a = 2444 ng/ml, b = 119.9 days, n = 7.6 for the control
group) (Table 1, Figure 6).
27
Table 1. Estimated values for a , b , and n for individual animals, and p-values used
to test significance of the estimated values.
Animal a (ng/ml) b (days) n
Rapid-progressor morphine group
1/04L 1.50 0.30 1.99
1/28Q 1.50 0.30 1.99
1/42N 1.50 0.30 1.99
Median 1.50 0.30 1.99
Slow-progressor morphine group
1/52N 6264 223.60 2.20
1/56L 557 109.30 6.99
1/02N 256 92.00 5.66
Median 557 109.30 5.66
Control group
2/31P 3128 118.50 10.50
2/02P 2028 121.60 4.70
2/AC42 1359 127.90 13.20
MAC-1 2860 81.40 3.00
MAC-2 2026 56.90 11.00
MAC-3 3800 121.30 1.40
Median 2444 119.90 7.60
p-value
Rapid vs. Slow-progressor morphine group 0.3511 0.0758 0.1739
Slow-progressor morphine vs. control group 0.9376 0.4678 0.3697
Rapid-progressor morphine vs. control group 0.0009 0.0003 0.0444
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Figure 5. Fitted curves to virus-specific antibody levels from individual animals
(the rapid-progressor morphine group: 1/04L, 1/28Q, 1/42N; the slow-progressor
morphine group: 1/52N, 1/56L. 1/02N; the control group: 2/31P, 2/02P, 2/AC42,
MAC-1, MAC-2, MAC-3).
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Figure 6. Virus-specific antibody curve plotted using median values of a , b , and n .
When we compare the slow-progressor morphine group with the control group,
we found that none of the antibody curve related parameters are significantly different
(Table 1), showing that in the slow-progressor morphine group morphine has minimal
effect on the measured antibody responses. However, we note that animal “1/52N”
has an extremely high estimated value, a = 6264 ng/ml, while all other animals have
a value of a less than 3800 ng/ml. Also, the set point CD4 count of this animal
remains extremely high throughout the infection; its set point CD4 count is higher
than 700 cells/µL , while the maximum set point CD4 count of all other animals in
the morphine group is 39 cells/µL . Excluding animal 1/52N, the value of a in the
slow-progressor morphine group is significantly lower than that in the control group
(p < 0.05).
Between the two morphine groups (rapid-progressor and slow-progressor), none
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of the antibody curve related parameters are significantly different (Table 1). Again,
excluding animal “1/52N”, and using two sample t-test with equal but unknown vari-
ances, all of a , b , and n become significantly different (p < 0.05) between the two
groups of animals under morphine conditioning. While the effects of morphine on
altering antibody responses can be quite variable among animals, the antibody re-
sponses can be severely hampered in some animals due to the presence of morphine.
Viral dynamics model selection
To identify the important model components representing the effect of morphine-
altered antibody responses on explaining viral dynamics, we considered 7 other differ-
ent variants of model (3.1) in which we leave out one or more hypothesized effects of
virus-specific antibody on viral neutralization, enhanced virion clearance or antibody-
mediated cellular loss and then compared them based on the Akaike’s Information
Criterion (AIC) values of the best fit to the median viral load data for the first 28
weeks post-infection (Table 2). The antibody response curve A(t) presented earlier
was used in each of these models. For a fair comparison of models, we made six
parameters free in each case. The parameters fitted in each model are listed in Table
2. Model-2 that only incorporates the effect of antibodies on virus neutralization and
enhanced virus clearance had the lowest AIC (Table 2). However, other models, e.g.,
models 4, 5 and 6 also had low values of AIC. We further examined in detail whether
Model-2 was the best one by fitting individual animal data to the full model, i.e.
model-1. In this case, we obtained extremely small values of γ (on the order of 10−9 )
in most of the animals (Table 3), asserting that there is almost no effect of antibodies
on infected cell killing. We also performed the fittings for A(t) using a spline curve
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fit to the virus-specific antibody response in each animal and found that the fitting
was not improved. In addition, the explicit formula for A(t) (equation (3.2)) allows
clear comparison between the different groups. Therefore, we use A(t) given by equa-
tion (3.2) and model-2, which has the lowest AIC value, to provide further results on
morphine-altered antibody responses.
Table 2. Fitted parameters, calculated Akaike’s Information Criterion (AIC) values
and Sum of Squared Residuals (SSR) for model fits to median data for each model.
Model Fitted
parameters
Rapid-
progressor
morphine
group
Slow-
progressor
morphine
group
Control
group
SSR AIC SSR AIC SSR AIC
Model-1 (Basic model) η, γ, σ, λ, r, q 8.30 125.3 3.37 7.6 2.65 9.4
Model-2 (γ = 0) η, δ, σ, λ, r, q 6.17 122.6 3.13 6.5 2.38 7.9
Model-3 (η = 0) βl, γ, σ, λ, r, q 8.28 125.3 3.36 7.6 4.02 15.2
Model-4 (σ = 0) η, γ, c, λ, r, q 7.46 124.3 3.27 7.1 2.87 10.3
Model-5 (γ = η = 0) βl, δ, σ, λ, r, q 8.37 125.3 3.19 7.0 2.42 8.2
Model-6 (γ = σ = 0) η, δ, c, λ, r, q 8.08 125.0 3.38 7.7 2.45 8.3
Model-7 (σ = η = 0) βl, γ, c, λ, r, q 8.18 125.1 3.26 7.1 2.78 10.1
Model-8 (σ = η = γ = 0) βl, δ, c, λ, r, q 8.09 125.0 3.69 9.0 5.21 18.8
32
Table 3. Model-1 estimated parameters for individual animals and their 95% confi-
dence intervals in parentheses.
Animal λ (cell ml−1
day−1)
r (day−1) q (day−1) η (ml ng−1) γ (ml ng−1
day−1)
σ (ml ng−1
day−1)
Rapid-progressor morphine group
1/04L 3630 (3311-3995) 0.22 (0.08-0.40) 1.2×10−4
(5.4×10−5-
3.4×10−4)
1.2 ×10−5
(1.2×10−6-
3.7×10−5)
1.0×10−8
(4.7×10−10-
3.7×10−8)
2.0×10−5
(1.8×10−6-
4.2×10−5)
1/28Q 3630 (3400-3870) 0.21 (0.07-0.45) 1.5×10−5
(4.1×10−4-
3.4×10−4)
1.4 ×10−5
(5.1×10−6-
3.2×10−5)
1.0×10−8
(1.6×10−9-
3.6×10−8)
1.3×10−5
(4.7×10−6-
3.9×10−5)
1/42N 3630 (3307-4021) 0.25 (0.18-0.84) 1.6×10−4
(6.3×10−5-
3.0×10−4)
1.0 ×10−5
(6.5×10−6-
2.7×10−5)
1.1×10−8
(6.5×10−9-
3.5×10−8)
1.1×10−5
(5.0×10−6-
3.8×10−5)
Slow-progressor morphine group
1/52N 3629 (3628-3629) 0.29 (0.21-0.32) 0.25 (0.19-0.29) 2.8 ×10−4
(1.3×10−4-
3.6×10−4)
1.1×10−5
(3.0×10−6-
3.4×10−5)
1.1×10−3
(1.1×10−4-
2.6×10−3)
1/56L 3630 (3580-3674) 0.22 (0.17-0.32) 0.20 (0.11-0.29) 1.0 ×10−4
(2.4×10−4-
2.5×10−4)
1.0×10−9
(2.5×10−9-
2.7×10−9)
1.0×10−4
(2.4×10−4-
2.5×10−4)
1/02N 3630 (3629-3630) 0.21 (0.16-0.26) 0.20 (0.15-0.25) 1.0 ×10−4
(4.8×10−5-
3.3×10−4)
5.9×10−4
(3.4×10−4-
8.0×10−4)
4.8×10−3
(2.7×10−3-
6.5×10−3)
Control group
2/31P 3630 (3626-3633) 0.17 (0.13-0.20) 0.24 (0.18-0.28) 1.3 ×10−4
(7.9×10−5-
1.8×10−4)
1.0×10−9
(1.1×10−10-
2.4×10−9)
1.0×10−4
(3.1×10−6-
2.2×10−4)
2/02P 3630 (3628-3630) 0.20 (0.13-0.22) 0.22 (0.09-0.26) 2.0 ×10−4
(1.2×10−5-
2.0×10−4)
9.8×10−9
(4.6×10−9-
1.6×10−8)
2.0×10−4
(7.4×10−6-
2.0×10−4)
2/AC42 3630 (3613-3643) 0.20 (0.15-0.36) 0.34 (0.33-0.45) 1.0 ×10−4
(4.3×10−5-
1.9×10−4)
1.6×10−4
(3.4×10−5-
3.0×10−4)
1.0×10−4
(2.1×10−5-
2.0×10−4)
MAC-1 3631 (3627-3635) 0.18 (0.13-0.30) 0.20 (0.10-0.30) 1.0 ×10−4
(1.5×10−5-
2.8×10−4)
1.0×10−9
(2.9×10−10-
2.7×10−9)
1.0×10−4
(5.2×10−6-
3.5×10−4)
MAC-2 3630 (3629-3631) 0.14 (0.08-0.19) 0.20 (0.08-0.26) 1.0 ×10−4
(1.6×10−5-
2.4×10−4)
1.1×10−9
(1.0×10−9-
1.9×10−9)
1.0×10−4
(5.6×10−6-
2.3×10−4)
MAC-3 3631 (3548-3694) 0.20 (0.20-0.42) 0.27 (0.14-0.45) 1.0 ×10−4
(7.8×10−6-
3.5×10−4)
1.0×10−9
(2.3×10−10-
2.8×10−9)
1.0×10−4
(9.3×10−6-
3.7×10−4)
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Variation of parameter estimates among animals in three groups
Using the antibody response curve A(t) (Eq. 3.2) as a known function in
model-2, we estimated the parameters by fitting the viral load data from the indi-
vidual animals in the rapid-progressor morphine, the slow-progressor morphine and
the control groups. These parameter estimates along with the 95% bootstrap confi-
dence intervals of the estimated parameters are given in Table 4. The corresponding
best-fits to the data from each animal and the median data of the three groups of
animals are shown in Figure 7. Among the estimated parameters, we found that the
scaling factor associated with the effect of virus-specific antibody responses on virus
neutralization,η , and the transition rate from Th to Tl , q , are significantly different
between the rapid-progressor and the slow-progressor morphine groups, and between
the rapid-progressor morphine and the control groups (p < 0.05). This observation
is consistent with results discussed in Vaidya et al. [87]. Similarly, as in the previous
study [87], the estimated parameter values for the transition rate from Tl to Th , r ,
are higher in the morphine-dependent groups than in the control group. However,
this difference was not statistically significant (p > 0.05). This could be because of
the smaller number of animals in the two morphine groups, as the morphine treated
animals were subdivided into two groups in this study and/or because of consideration
of our model over a longer period of time during which virus-specific antibodies play
important roles in virus dynamics (Figure 6). In addition, we did not observe any
significant difference in the other estimated parameters (p > 0.05) among the groups.
As shown by our median data best-fit curves (Figure 7), we observe a higher set-point
viral load in the rapid-progressor and in the slow-progressor morphine groups than
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in the control group (5.4 log10 in the rapid-progressor morphine group, 5.2 log10 in
the slow-progressor morphine group, and 4.2 log10 in the the control group). This
observation is consistent with the experimental results in Kumar et al. [37].
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Table 4. Model-2 estimated parameters for individual animals, fitted parameter
values to median data and their 95% confidence intervals in parentheses, and
the mean values of A calculated over a period of 200 days post infection using
¯A =
1
200
∫ 200
0
(
ηA(t)
1+ηA(t)
)
dt .
Animal λ (cell ml−1
day−1)
r (day−1) q (day−1) δ (day−1) σ (ml ng−1
day−1)
η (ml ng−1) mean value
(¯A)
Rapid-progressor morphine group
1/04L 3630 (3396-
3901)
0.20 (0.14-
0.28)
1.1×10−4
(1.5×10−5-
2.1×10−4)
0.56 (0.43-0.75) 2.8×10−3
(6.8×10−4-
5.1×10−3)
1.0×10−4
(1.8×10−6-
1.9×10−4)
1.5×10−4
1/28Q 3773 (3322-
4481)
0.24 (0.18-
0.48)
1.0×10−4
(2.6×10−5-
1.4×10−4)
0.80 (0.68-0.94) 2.3×10−3
(8.0×10−5-
3.0×10−3)
1.1×10−4
(1.9×10−8-
1.2×10−4)
1.6×10−4
1/42N 5000 (4688-
5278)
0.40 (0.16-
0.69)
1.2×10−4
(8.5×10−6-
2.5×10−4)
0.30 (0.26-0.53) 2.3×10−3
(2.3×10−4-
4.6×10−3)
1.1×10−4
(2.8×10−6-
1.9×10−4)
1.6×10−4
Median
data
3630 (3440-
3835)
0.16 (0.06-
0.34)
1.0×10−2
(1.4×10−5-
2.0×10−2)
0.31 (0.09-0.47) 1.1×10−2
(7.4×10−3-
1.4×10−2)
1.9×10−6
(4.1×10−7-
3.3×10−6)
2.8×10−6
Slow-progressor morphine group
1/52N 3631 (3629-
3632)
0.38 (0.31-
0.47)
0.21 (0.08-0.35) 0.53 (0.44-0.63) 1.5×10−2
(1.2×10−2-
1.8×10−2)
1.0×10−6
(1.3×10−7-
2.0×10−6)
1.1×10−3
1/56L 3629 (3627-
3631)
0.41 (0.28-
0.62)
0.18 (0.04-0.34) 0.32 (0.24-0.36) 2.3×10−6
(1.5×10−7-
4.4×10−6)
1.0×10−6
(6.8×10−8-
1.8×10−6)
2.4×10−4
1/02N 3630 (3511-
3757)
0.18 (0.15-
0.22)
0.10 (0.02-0.18) 0.75 (0.55-0.96) 3.0×10−2
(1.2×10−2-
4.8×10−2)
1.1×10−6
(2.6×10−8-
1.9×10−6)
1.5×10−4
Median
data
3629 (3527-
3630)
0.17 (0.11-
0.22)
0.10 (0.02-0.21) 0.65 (0.42-0.68) 3.4×10−3
(1.0×10−3-
5.5×10−3)
1.0×10−6
(3.3×10−7-
2.6×10−6)
2.4×10−4
Control group
2/31P 3629 (3593-
3661)
0.31 (0.23-
0.41)
0.68 (0.51-0.91) 0.31 (0.24-0.34) 7.1×10−3
(5.5×10−3-
1.0×10−2)
1.0×10−6
(1.1×10−7-
2.0×10−6)
1.2×10−3
2/02P 4050 (3969-
4125)
0.18 (0.13-
0.24)
0.20 (0.10-0.34) 0.66 (0.40-0.74) 2.3×10−3
(7.1×10−4-
4.4×10−3)
1.0×10−4
(3.4×10−5-
2.0×10−4)
6.6×10−2
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2/AC42 3630 (3627-
3632)
0.14 (0.11-
0.18)
0.33 (0.14-0.46) 0.54 (0.46-0.61) 5.3×10−4
(2.8×10−4-
3.0×10−3)
4.9×10−5
(1.2×10−7-
1.9×10−6)
2.2×10−2
MAC-1 3630 (3115-
3893)
0.13 (0.10-
0.25)
0.18 (0.07-0.29) 0.38 (0.16-0.39) 2.3×10−3
(3.0×10−4-
3.4×10−3)
1.0×10−4
(1.4×10−5-
1.5×10−4)
1.3×10−1
MAC-2 3629 (3610-
3647)
0.13 (0.10-
0.16)
0.28 (0.12-0.45) 0.61 (0.40-0.82) 3.2×10−6
(7.1×10−7-
5.9×10−6)
1.0×10−7
(9.9×10−9-
2.0×10−6)
1.4×10−4
MAC-3 3630 (3574-
3684)
0.16 (0.08-
0.29)
0.24 (0.06-0.43) 0.40 (0.24-0.53) 2.3×10−6
(1.4×10−7-
4.6×10−6)
1.0×10−6
(5.9×10−8-
2.0×10−6)
1.5×10−3
Median
data
3630 (3628-
3631)
0.15 (0.12-
0.19)
0.18 (0.07-0.31) 0.65 (0.41-0.81) 2.5×10−3
(1.1×10−3-
4.4×10−3)
1.1×10−6
(2.2×10−7-
2.7×10−6)
1.0×10−3
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Figure 7. Best-fit viral dynamics curve using model-2 (solid line) to the experimental
viral load data (•) for individual animals (rapid-progressor morphine group: 1/04L,
1/28Q, 1/42N; slow-progressor morphine group: 1/52N, 1/56L. 1/02N; control group:
2/31P, 2/02P, 2/AC42. MAC-1, MAC-2, MAC-3), and to the median viral load data
for the rapid-progressor morphine group, the slow-progressor morphine group, and
the control group.
Effects of morphine-altered antibody responses on virus neutralization and
enhanced viral clearance
As revealed by our data fitting procedure, the main effects of virus specific
antibody responses are the neutralization of virus and enhancement of viral clearance.
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To quantify these effects due to morphine, we computed the efficacy of virus-specific
antibodies in reducing the infection rate, A , and the rate of enhanced virus clearance,
σA(t), for each group of animals. Our results at the end of the 200 day post infection
period clearly show lower efficacy of antibody responses to reduce virus infection in
the morphine-dependent groups (almost 100% lower in the rapid-progressor and 79%
lower in the slow-progressor) when compared to A = 2.6× 10−3 of the control group
(Figure 8). We also calculated the mean value of A (Table 4) over the time course
of 200 days post infection and found that the mean antibody neutralization efficacy
was lower in the morphine group (99.7% lower in the rapid-progressor and 76% lower
in the slow-progressor) than the control group (A = 1.0× 10−3 ). Similarly, we found
that the rate of enhanced virus clearance for the 200 day post-infection period is
lower in the rapid-progressor morphine group (almost 100% lower), and in the slow-
progressor morphine group (69% lower) when compared to the control group (6.1
day−1 ) (Figure 8). The mean value of σA(t) over the time course of 200 days post
infection is 99.2% lower in the rapid-progressor morphine group, 65% lower in the
slow-progressor morphine group when compared to the control group (2.4 day−1 ).
These results suggest that morphine can alter the antibody responses resulting in
substantial effects on virus dynamics.
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Figure 8. Predicted effects of morphine-altered virus-specific antibody responses on
virus neutralization and enhanced virus clearance. The horizontal lines show the
mean values of A and σA(t) for each group calculated over a period of 200 days post
infection using ¯A =
1
200
∫ 200
0
(
ηA(t)
1+ηA(t)
)
dt and ¯σA(t) = 1
200
∫ 200
0
σA(t)dt .
Effects of morphine-altered antibody response on CD4 count
Using our model, we predicted the dynamics of the count (Figure 9) and
estimated the CD4 loss in the first 200 days post infection. The morphine group
showed a lower CD4 count compared to the control group. At 200 days post-infection,
we predict the CD4 count to be 70 cells/µL for the rapid-progressor morphine group
and 152 cells/µL for the slow-progressor morphine group, while in the control group
it is maintained at 185 cells/µL . With this prediction, we found a greater CD4 loss in
the morphine-dependent groups (93% and 85% in the rapid-progressor and the slow-
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progressor morphine groups, respectively) than the control group (82% loss) (Figure
9). We note that the CD4 data is more chaotic and not frequent enough to use
for longer period fitting. However, we compared our results with the experimentally
measured values of the CD4 count [37, 38], in which a loss of 99% at week 14 in
the rapid-progressor morphine group, 97% loss at week 28 in the slow-progressor
morphine group and 83% loss at week 28 of the control group were observed. This
shows that our model predictions are qualitatively consistent with the experimentally
measured values, but with a slight difference in magnitude.
Figure 9. Predicted effects of morphine-altered virus-specific antibody responses on
CD4 count and CD4 loss.
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Basic reproduction number (R0 )
We examine how morphine conditioning affects the basic reproduction number,
defined as the average number of secondary infections occurring from a single infected
cell introduced into a population of entirely uninfected cells. It can be shown that
if R0 < 1, infection is avoided and if R0 > 1, infection is established [89]. With
A(t) = A(0), we can derive the basic reproduction number of our model using the
next-generation method [89] outlined in chapter 2.
The model system 3.1 has exactly one infection-free equilibrium
X0 =
(
λ(d+ q)
d(d+ r + q)
,
λr
d(d+ r + q)
, 0, 0
)
,
and equations for the infected cell and virus compartments of the linearized system
at X0 take the form
dI
dt
=
λ
d(d+ r + q)
(βl(d+ q) + βhr) (1− A(0))V − δI, (3.4)
dV
dt
= pI − cV − σA(0)V.
We introduce the following two matrices:
F =
 0 λd(d+r+q) (βl(d+ q) + βhr) (1− A(0))
0 0
 , V =
 δ 0
−p c+ σA(0)
 .
These expressions give
FV−1 =
 λp(βl(d+q)+βhr)(1−A(0))δd(d+r+q)(c+σA(0)) λ(βl(d+q)+βhr)(1−A(0))d(d+r+q)(c+σA(0))
0 0
 ,
Then R0 corresponds to the dominant eigenvalue of FV−1, that is
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R0 = λp (βl(d+ q) + βhr) (1− A(0))
δd(d+ r + q)(c+ σA(0))
.
Using our parameter estimates in this formula, we obtained RR0 = 6.48 (for the rapid-
progressor morphine group), RS0 = 2.12 (for the slow-progressor morphine group),
and RC0 = 1.55 (for the control group). Since R0 > 1 in all three groups, infection is
predicted to occur in all the groups consistent with the data. Morphine does not seem
to have role in determining establishment of the infection. However, having a higher
value of R0 in the rapid-progressor morphine group indicates that the morphine may
cause an extra obstacle that needs to be overcome in order to avoid infection by
pre-exposure prophylaxis (PrEP). These estimated R0 values indicate that the effec-
tiveness of PrEP required to prevent infection is at least 85% in the rapid-progressor
morphine group, while 53% effectiveness and 36% effectiveness are needed to prevent
infection in the slow-progressor morphine group and the control group, respectively.
CHAPTER 4
EFFECTS OF MORPHINE PHARMACODYNAMICS ON HIV-INFECTION
DYNAMICS
In this chapter, we develop a model to analyze the effects of periodic morphine
intake. We consider two cases, namely, intravenous morphine (IVM), and slow-release
oral morphine (SROM) and integrate several morphine pharmacodynamic parame-
ters related to these cases into our HIV-infection dynamics model. We show how
time-varying changes in morphine concentration and the time-varying HIV-specific
antibody responses affects the viral infection threshold, viral load, and the CD4 count.
Introduction
In chapter 3, we developed a model incorporating the effects of morphine-
altered virus specific antibody responses on viral dynamics. We obtained interesting
results for constant morphine conditioning. These results provided the need to ex-
amine whether periodic morphine intake produces similar effects. It is possible that
periodic morphine intake can result to time-varying antibody responses effects within
HIV-infected individuals thereby causing periodic virus neutralization and periodic
virus clearance. It is therefore important to examine what effects periodic morphine
intake can have on HIV viral dynamics. To study these effects, we consider two cases
of morphine intake: intravenous morphine (IVM) and slow-release oral morphine
(SROM).
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Model development
We develop a pharmacodynamic morphine effect model by incorporating time-
varying efficacy (ΩI(t)) of virus-specific antibodies in the reduction of virus infec-
tivity, and time-varying enhancement (Ωc(t)) of virus clearance due to antibody
binding to cell-free virus. The schematic diagram of the model is presented in
Figure 11. Here, ΩI(t) =
ηA(t)
1+ηA(t)
and Ωc(t) = σA(t), where A(t) represents the
time-varying HIV-specific antibodies responses which depend on morphine concentra-
tion. We model the time-varying HIV-specific antibody responses using the formula
A(t) =
(
1− M(t)n
Mnh+M(t)
n
)
, where M(t) is a function that represents morphine con-
centration at time t (see Eq. 4.2 and 4.3), Mh represents the time when morphine
concentration becomes half, and n is the Hill coefficient. The A(t) is formulated in
such a way that its value lies between 0 and 1 with A(t) = 0 for a very high morphine
concentration (i.e., M(t)→∞) and A(t) = 1 (maximum) in the absence of morphine
(i.e., M(t) = 0), consistent with the results in chapter 3 on the effect of morphine
on antibody responses. An example of a graph describing the dynamics of antibody
responses (A(t)) in morphine concentration is given in Figure 10 (a).
In our model, we assume that under periodic intake of morphine, time-varying
parameters ΩI(t), Ωc(t) become periodic functions of period τ , i.e., ΩI(t) = ΩI(t+τ)
and Ωc(t) = Ωc(t+ τ), respectively.
We describe the infection dynamics using the following set of equations:
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dTl
dt
= λ+ qTh − dTl − rTl − (1− ΩI(t))βlV Tl, Tl(0) = Tl0
dTh
dt
= rTl − dTh − qTh − (1− ΩI(t))βhV Th, Th(0) = Th0
dI
dt
= (1− ΩI(t))βlV Tl + (1− ΩI(t))βhV Th − δI, I(0) = I0 (4.1)
dV
dt
= pI − cV − Ωc(t)V, V (0) = V0
Morphine concentration profile, M(t)
Intravenous morphine (IVM). In this case, morphine is directly injected into
the blood stream. One reason why IVM may be prefered by drugs of abuse users
is that its direct administration into the circulation provides a rapid effect [50]. A
previous study on phamarcokinetics and pharmacodynamics of opioids [45] has shown
that intravenous administration of drugs is best described by an exponential decay
function. Thus, we consider a function of the form M(t) = a0e
−b1t to explain the
dynamics of intravenous morphine for a period of single intake. Therefore for a
periodic intake of IVM we model the morphine concentration as
M(t) = a0e
−b1(t−tk), tk ≤ t < tk+1 k = 0, 1, 2, ... (4.2)
where, ∆t = tk+1 − tk represents morphine intake time interval, a0 represents the
morphine dose, and b1 denotes the decay rate. Note that t1/2 = log(2)/b1 (see Figure
10 (b) for a graph describing the M(t) dynamics for the IVM case).
Slow-release oral morphine (SROM). In this case, morphine is taken orally
and can be used as a maintenace pharmacotherapy treatment for opioid-dependent
individuals who respond poorly to other available maintenance treatments [26]. It
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has also been reported that SROM may be associated with reduced opioid craving
[7, 23, 27, 31, 36, 51, 90]. Moreover, the use of SROM among HIV-infected persons
may present an additional safety advantage due to its lower risk with interactions
with other drugs [74]. It is important to study the effects of SROM conditioning on
HIV-infected persons. In using the SROM as a maintenance treatment, it is critical
to strike the right balance between the need for the drug and its addictivity. In oral
morphine intake, the concentration of morphine in the blood slowly increases and then
decreases after it reaches a peak. This phenomena can approximately be captured
using a function of the form
M(t) = M0 + a sin(τt+ b) (4.3)
where, M0 represents the mean level of morphine, a denotes the amplitude, and b
represents the phase shift in the function. (see Figure 10 (c) for a graph describing
the M(t) dynamics for the SROM case).
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Figure 10. (a) Morphine concentration (M(t)) vs antibody responses (A(t)) at time
t , and morphine concentration dynamics for (b) IVM case and (c) SROM case
.
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Figure 11. Schematic diagram of the pharmacodynamics of morphine model.
49
Table 5. Model (4.1) parameter values and their interpretations.
Description Parameter Estimate Source
Reproduction rate of T cells λ 3630 cells ml−1
day−1
[87]
Infection rate of Tl βl 2.29 × 10−9
day−1
Estimate, [87]
Infection rate of Th βh 2.29 × 10−7
day−1
Estimate, [87]
Death rate of uninfected T cells d 0.01 day−1 [75, 52]
Death rate of infected T cells δ 0.65 day−1 Estimate, [87]
Virion production rate p 2500 day−1 [87]
Virion clearance rate c 23 day−1 [66]
Transition rate from Tl to Th r 0.15 day
−1 [87]
Transition rate from Th to Tl q 0.18 day
−1 [87]
Net A(t) effect scaling factor η 0.8 ml ng−1 Assumed
Net A(t) effect scaling factor σ 0.5 day−1 Assumed
Time morphine concentration is half Mh 50 days Assumed
Hill’s coefficient n 5 Assumed
Morphine dose a0 100 [0− 200] Varied
Morphine half life b1 4 [1−10] hours Varied
Morphine mean level M0 100 [50− 200] Varied
Amplitude a 50 [0− 100] Varied
Drug intake interval ∆t, τ 8 [2−22] hours Varied
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Viral infection threshold (Ri)
Because of the periodic conditions described by our model (4.1), a more real-
istic measure for when an infection can die out or persist can best be described using
an infection threshold, which is described in this section.
Using a similar approach to that of Wang and Zhao [91], Liu, Zhao and Zhou
[42], Vaidya and Rong [88], and Vaidya and Wahl [86], we now derive the viral in-
fection threshold, Ri. We consider the model system 4.1 with τ -periodic functions
ΩI(t) and Ωc(t). The equations for the infected cells and virus compartments of the
linearized system at the infection-free equilibrium, X0 , take the form
dI
dt
= −δI + λ
d(d+ r + q)
(βl(d+ q) + βhr) (1− ΩI(t))V, (4.4)
dV
dt
= pI − cV − Ωc(t)V.
We consider
Fτ (t) =
 0 λd(d+r+q) (βl(d+ q) + βhr) (1− ΩI(t))
0 0
 , Vτ (t) =
 δ 0
−p c+ Ωc(t)
 .
We assume that Y (t, s), t ≥ s is the evolution operator of the linear τ -periodic
system
dy
dt
= −Vτ (t)y (4.5)
That is, for each s ∈ R , the 2× 2 matrix Y (t, s) satisfies
d
dt
Y (t, s) = −Vτ (t)Y (t, s) ∀t ≥ s, Y (s, s) = I,
where I is the 2 × 2 identity matrix. Then the monodromy matrix, Φ−Vτ (t) of (4.5), is
equal to Y (t, 0), t ≥ 0.
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Let φ(s) be the initial distribution of virus particles. Then Fτφ(s) is the rate of
new infected cells produced by the virus particles which were introduced at time s. Given
t ≥ s , then Y (t, s)Fτφ(s) provides the distribution of those virus particles which were
newly produced by infected cells at time s and remain in the virus compartment at time t.
Let Cτ be the ordered Banach space of τ -periodic functions from R to R2 with
the maximum norm ‖.‖ and the positive cone C+τ := {φ ∈ Cτ : φ(t) ≥ 0 ∀t ∈ R} . We now
define a linear operator L : Cτ → Cτ by
(Lφ)(t) =
∫ ∞
0
Y (t, t− a)Fτφ(t− a) ∀t ∈ R, φ ∈ Cτ
Here,
∫∞
0 Y (t, t − a)Fτφ(t − a)da =
∫ t
−∞ Y (t, s)Fτφ(s)ds gives the distribution of accu-
mulated new viruses at time t produced due to all those viruses φ(s) at times before t.
Therefore, L is the next infection operator [86, 91], and we define infection threshold as
Ri = ρ(L), the spectral radius of L.
As in Wang and Zhao [91] and Liu, Zhao and Zhou [42], we let W(t, θ) be the
monodromy matrix of the linear τ -periodic system
dτ
dt
=
(
−Vτ (t) + Fτ (t)
θ
)
τ, t ∈ R, (4.6)
with parameter θ ∈ (0,∞). Since Fτ is non-negative and −Vτ (t) is co-operative, it follows
that limθ→∞ ρ(W(τ, θ)) < 1. and ρ(W(τ, θ)) is continuous and non increasing in θ ∈ (0,∞).
Thus, as proved in Wang and Zhao [91], we have the following results.
LEMMA 4.1. The following statements hold
(i) If ρ(W(τ, θ)) = 1 has a positive solution θ0 , then θ0, is an eigenvalue of operator L,
and hence Ri > 0.
(ii) If Ri > 0, then θ = Ri is the unique solution of ρ(W(τ, θ)) = 1.
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(iii) Ri = 0 if and only if ρ(W(τ, θ)) < 1 for all θ > 0.
THEOREM 4.2. (see [91]). The infection-free equilibrium X0 is locally asymptotically
stable if Ri < 1, and unstable if Ri > 1.
Global dynamics
By deriving a condition for the global stability of X0 in the following theorem, we
establish that the condition for global eradication of the virus from the body is given by
Ri < 1.
THEOREM 4.3. If Ri < 1, then the unique infection-free equilibrium,
X0 =
(
λ(d+ q)
d(d+ r + q)
,
λr
d(d+ r + q)
, 0, 0
)
,
is globally asymptotically stable.
PROOF. Let Ri < 1. Then Theorem 4.2, implies that X0 is locally asymptotically
stable, i.e., ρ(ΦFτ−Vτ (τ)) < 1. We can choose j0 > 0 small enough giving ρ(ΦG(j0)(τ)) < 1,
where
G(j0)(t) =
 −δ
(
λ(d+q)
d(d+r+q) + j0
)
βl(1− ΩI(t)) +
(
λr
d(d+r+q) + j0
)
βh(1− ΩI(t))
p −(c+ Ωc(t))

From the first and the second equations of system (4.1), we have dTldt ≤ λ+ qTh − (d+ r)Tl
and dThdt ≤ rTl − (d + q)Th . This implies that Tl(t) ≤ Tˆl(t) → λ(d+q)d(d+r+q) as t → ∞ and
Th(t) ≤ Tˆh(t) → λrd(d+r+q) as t → ∞ . Therefore, for j0 > 0, there exists tj0 such that
Tl(t) ≤ λ(d+q)d(d+r+q) + j0, Th(t) ≤ λrd(d+r+q) + j0 ∀t ≥ tj0 . Then from the third and the fourth
equations of system (4.1), we have
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dI
dt
≤ −δI +
(
λ(d+ q)
d(d+ r + q)
+ j0
)
βl(1− ΩI(t))V +
(
λr
d(d+ r + q)
+ j0
)
βh(1− ΩI(t))V,
dV
dt
= pI − cV − Ωc(t)V. (4.7)
Now, consider the following comparison system
dIˆ
dt
= −δIˆ +
(
λ(d+ q)
d(d+ r + q)
+ j0
)
βl(1− ΩI(t))Vˆ +
(
λr
d(d+ r + q)
+ j0
)
βh(1− ΩI(t))Vˆ ,
dVˆ
dt
= pIˆ − cVˆ − Ωc(t)Vˆ . (4.8)
According to Zhang and Zhao [97], there exists a positive, τ -periodic function (I¯(t), V¯ (t))T
such that (Iˆ(t), Vˆ (t))T = eΘt(I¯(t), V¯ (t))T is a solution of system (4.8), where
Θ =
1
τ
ln(ρ(ΦG(j0)(τ))).
Here, ρ(ΦG(j0)(τ)) < 1 =⇒ Θ < 0, which implies (Iˆ(t), Vˆ (t))T → (0, 0)T as t → ∞ .
Therefore, the (0, 0)T solution of system (4.8) is globally asymptotically stable.
For any non-negative initial value (I(0), V (0))T of system (4.7), we can choose a suf-
ficiently large m > 0 satisfying (I(0), V (0))T ≤ m(I¯(0), V¯ (0))T . Clearly, m(Iˆ(t), Vˆ (t))T =
meΘt(I¯(t), V¯ (t))T is also a solution of (4.8). Then applying the comparison principle [73],
we get (I(t), V (t))T ≤ m(Iˆ(t), Vˆ (t))T ∀t > 0. Therefore we get I(t) → 0 and V (t) → 0
as t → ∞ . Then, by the theory of asymptotically autonomous systems [79], we get
Tl(t) → λ(d+q)d(d+r+q) and Th(t) → λrd(d+r+q) as t → ∞ . Hence, Ri < 1 gives a condition
for X0 to be globally asymptotically stable. unionsqu
Effects of morphine pharmacodynamics on HIV dynamics
According to Lemma 4.1, the infection threshold (Ri ) can be obtained by solving
ρ(W (τ, θ)) = 1 for θ . Therefore, using our model (4.1), in the form of system (4.6), we
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computed Ri numerically to study how Ri depends on the pharmacodynamic parameters
a0 , t1/2 , M0 , and a . As seen in Figures 12 and 14, each of these parameters can affect Ri .
Note that the range of these parameters considered do not make Ri less than 1, thereby
causing the infection to remain persistent. Furthermore, we used our model (4.1) to evaluate
the influence of the pharmacodynamic parameters on the dynamics of viral load and CD4
count in both IVM and SROM cases.
Intravenous morphine (IVM) case
As seen in Figure 12, an increase in morphine dose and/or a half-life increases the
infection threshold (Ri ). In particular, a morphine dose greater than 50 (i.e., a0 > 50)
causes a faster increase in Ri (Figure 12 (a)). Also, we observe that a decrease in morphine
intake interval from 22 hours to 2 hours (Figure 12 (c)) increases the infection threshold
from 3.59 to 6.07.
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Figure 12. Viral infection threshold, Ri , as a function of (a) the morphine dose, a0 ,
(b) the half-life of morphine, t1/2 , and (c) the morphine intake interval.
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The results we obtain from varying the pharmacodynamic parameters show that an
increase in the morphine dose increases the viral load at the end of 200 days post infection
from −3.8 log 10 to 5.1 log 10 (Figure 13 (a)), with a more pronounced increase occurring
for morphine doses between 50 and 125. Also, increasing the half-life of morphine increases
the 200 days post infection viral load from −3.9 log 10 to 5.1 log 10 (Figure 13 (b)).
From Figures 13 (c) and 13 (d), we observe that an increase in the morphine dose,
as well as an increase in a half-life decreases the CD4 count from 354 to 256 cells/µL , and
from 353 to 260 cells/µL , respectively.
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Figure 13. Changes in viral load and CD4 count with varying morphine dose, a0 ,
and morphine half-life, t1/2 .
Slow-release oral morphine (SROM) case
Figures 14 (a) and 14 (b) show that an increase in the mean level of morphine
and/or a decrease in the amplitude increases the infection (Ri ). Specifically, we observe a
faster increase in Ri when the mean level is between 50 and 125 (i.e., 50 ≤ M0 ≤ 125),
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then almost no change in Ri when M0 > 125 (Figure 14 (a)). Furthermore, we see a faster
increase in Ri when the amplitude decreases from 100 to 25 (Figure 14 (b)). Our results
also show that decreasing morphine intake interval from 22 hours to 2 hours increases the
infection threshold from 5.89 to 6.20 (Figure 14 (c)). However, we observe that the effect
on Ri remains almost constant for morphine intake interval greater than 8 hours (Figure
14 (c)).
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Figure 14. Viral infection threshold, Ri , as a function of (a) the mean level of
morphine, M0 , (b) the morphine amplitude, a , and (c) the morphine intake interval.
Figure 15 (a) shows that an increase in the mean level of morphine increases the 200
day post infection viral load from 5.14 log 10 to 5.27 log 10 whereas an increase in the am-
plitude decreases the viral load at the 200 day post infection from 5.26 log 10 to 5.01 log 10
(Figure 15 (b)). These results suggest that the SROM pharmacodynamic parameters play
a minimal role in altering the viral load dynamics compared to the IVM case.
Our results on the effects of the SROM pharmacodynamic parameters on CD4 count
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show that an increase in the mean level of morphine dose decreases the CD4 count from 340
to 246 cells/µL (Figure 15 (c)). On the other hand, an increase in the amplitude increases
the CD4 count from 250 to 285 cells/µL (Figure 15 (d)).
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Figure 15. Changes in viral load and CD4 count with varying mean level of mor-
phine, M0 , and the morphine amplitude, a .
CHAPTER 5
EFFECT OF MORPHINE ON HIV-INFECTION WITH TWO VIRAL SPECIES
In this chapter, we develop and analyze a mathematical model to evaluate the effects
of morphine on the viral dynamics of HIV when two viral species, namely, the wild-type
virus and the mutant virus, are present in an individual. We calculate the reproduction
number (RB0 ) for each species both in the presence of morphine and in the absence of
morphine. We also perform the sensitivity analysis to identify the parameters that largely
affect RB0 . Using our model, we perform numerical simulations to study the effects of the
fitness cost of the mutant virus, and the effects of escape ratio on HIV dynamics under
morphine conditioning.
Introduction
As HIV infects a new cell, the virus releases its high genetic material in the form of
viral RNA and uses the reverse trascriptase protein to create a DNA copy of itself (Figure
2). The reverse transcription process is responsible for most mutations [5]. The production
of mutant viruses can present a significant challenge to the control of HIV as they can evade
detection by antibodies and other immune sytem components which play a significant role in
controlling the progression of an infection. Multiple infections of a host cell poses a greater
risk of increased mutation rate [5]. Experimental studies have shown that morphine can
affect the viral mutation as well as the cellular immune responses [69, 70, 80] and previous
studies have also suggested that viral escape might contribute to increased viral burden
and disease progression [2, 25, 30, 60]. However, the understanding of the viral escape in
the setting of drugs of abuse remains unclear. Therefore, it is important to understand the
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interplay between the use of morphine, the immune responses, the viral escape, and the
fitness cost on HIV dynamics in two viral species.
Model development
The ODE model we consider in this chapter further extends the model (3.1). Specifi-
cally, we include populations of wild-type viruses, V1 , and mutant viruses, V2 , in the model.
Upon interaction with the viruses V1 or V2 , the target cells, Tl and Th , become infected
cells I1 and I2 , respectively. The schematic diagram of the model is presented in Figure
16, and the model parameter values are given in Table 6.
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Figure 16. Schematic diagram of the model with two viral species.
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The wild-type virions infect target cells Tl and Th at rates βl1 and βh1 , respectively.
We let α represent the fitness cost of the mutant virus, a reduction in the mutant infection
rate relative to the wild-type infection rate caused by mutation [29, 82]. Thus, we assume
mutant virions infect the target cells Tl and Th at rates βl2 = (1 − α)βl1 and βh2 =
(1 − α)βh1 , respectively. We assume mutation occurs within a cell infected with the wild-
type virus (i.e. forward mutation) and denote the proportion of cells infected with the
wild-type virus that become mutant [35] by f , where 0 < f < 1. Previous studies utilizing
SIV have shown that less mutation occurs in the presence of morphine [54, 80]. To capture
this morphine effect on the mutation rate in our model, we take f = kµ+γM . Here, M
represents the morphine concentration, and the parameters k , µ , and γ are introduced to
model the lowered mutation rate caused by morphine [54, 55, 70, 82].
As in chapter 3, we take A =
ηA(t)
1+ηA(t) (3.3) to model the efficacy of virus neu-
tralization by antibodies with A(t) = at
n
bn+tn (3.2), where the values of a , b , and n are
provided in Table 1. Furthermore, antibodies enhance the clearance of the wild-type virus
at a per capita rate σ1A(t). Similarly, we denote enhanced clearance rate for the mutant
virus by σ2 = ψσ1 , where 0 ≤ ψ ≤ 1 represents the escape ratio, a reduction in the ability
of antibodies to destroy mutant viruses. The proposed model we study in this chapter is
therefore described by the following set of equations:
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dTl
dt
= λ+ qTh − dTl − rTl − (1− A) (βl1V1Tl − βl2V2Tl) , Tl(0) = Tl0
dTh
dt
= rTl − dTh − qTh − (1− A) (βh1V1Th − βh2V2Th) , Th(0) = Th0
dI1
dt
= (1− f)(1− A) (βl1V1Tl + βh1V1Th)− δ1I1, I1(0) = I10 (5.1)
dI2
dt
= (1− A) (fβl1V1Tl + fβh1V1Th + βl2V2Tl + βh2V2Th)− δ2I2, I2(0) = I20
dV1
dt
= p1I1 − c1V1 − σ1A(t)V1, V1(0) = V10
dV2
dt
= p2I2 − c2V2 − σ2A(t)V2. V2(0) = V20
Model analysis
The basic reproduction number (RB0 )
We derive the basic reproduction number, RB0 , for model (5.1) with A(t) = A(0).
The model system (5.1) has exactly one infection-free equilibrium
X0 =
(
λ(d+ q)
d(d+ r + q)
,
λr
d(d+ r + q)
, 0, 0, 0, 0
)
,
and the equations for the infectious and virus classes of the linearized system at X0 take
the form:
dI1
dt
=
λ(1− f)(1− A(0))
d(d+ r + q)
(βl1(d+ q) + βh1r)V1 − δ1I1,
dI2
dt
=
λ(1− A(0))
d(d+ r + q)
[f (βl1(d+ q) + βh1r)V1 + (βl2(d+ q) + βh2r)V2]− δ2I2,
dV1
dt
= p1I1 − c1V1 − σ1A(0)V1, (5.2)
dV2
dt
= p2I2 − c2V2 − σ2A(0)V2.
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We introduce the following two matrices:
FB =

0 0 λ(1−f)(1−A(0))d(d+r+q) (βl1(d+ q) + βh1r) 0
0 0 λf(1−A(0))d(d+r+q) (βl1(d+ q) + βh1r)
λ(1−A(0))
d(d+r+q) (βl2(d+ q) + βh2r)
0 0 0 0
0 0 0 0

,
and
VB =

δ1 0 0 0
0 δ2 0 0
−p1 0 c1 + σ1A(0) 0
0 −p2 0 c2 + σ2A(0)

.
These expressions give FBVB−1 as: X2×2 Y2×2
02×2 02×2
 ,
where
X =
 λp1(1−f)(1−A(0))[βl1(d+q)+βh1r]δ1d(d+r+q)(c1+σ1A(0)) 0
λp1f(1−A(0))[βl1(d+q)+βh1r]
δ1d(d+r+q)(c1+σ1A(0))
λp2(1−A(0))[βl2(d+q)+βh2r]
δ2d(d+r+q)(c2+σ2A(0))
 ,
Y =
 λ(1−f)(1−A(0))[βl1(d+q)+βh1r]d(d+r+q)(c1+σ1A(0)) 0
λf(1−A(0))[βl1(d+q)+βh1r]
d(d+r+q)(c1+σ1A(0))
λ(1−A(0))[βl2(d+q)+βh2r]
d(d+r+q)(c2+σ2A(0))
 .
Then RB0 corresponds to the spectral radius of FBVB−1 , that is
RB0 = ρ(FBVB−1) = max
{R10,R20}
where
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R10 =
λp1(1− f)(1− A(0)) [βl1(d+ q) + βh1r]
δ1d(d+ r + q)(c1 + σ1A(0))
, and
R20 =
λp2(1− A(0)) [βl2(d+ q) + βh2r]
δ2d(d+ r + q)(c2 + σ2A(0))
.
THEOREM 5.1. (See [89]) If RB0 < 1, then the infection-free equilibrium is locally
asymptotically stable and unstable if RB0 > 1.
Using the basic reproduction number formula derived above and the parameter
values in Table 6, we now calculate the basic reproduction number, RB0 . We obtained
R10 = 2.25 (for the wild-type virus) and R20 = 2.22 (for the mutant virus) when we have
very high (A(t) ≈ 2444, Figure 6) virus-specific antibody responses (i.e., in absence of
morphine) whereas when we have very low (A(t) ≈ 0, Figure 6) virus-specific antibody
responses (i.e., in presense of morphine), R10 = 2.85 (for the wild-type virus) and R20 = 2.28
(for the mutant virus). Therefore, RB0 = max
{R10,R20} = 2.25 (in absence of morphine)
and RB0 = max
{R10,R20} = 2.85 (in presence of morphine). We note that this basic
reproduction number estimate is consistent with previous estimates [87]. When compared
to the estimates obtained in chapter 3, we observe a consistency in that in the presence of
morphine we have higher estimate than in the absence of morphine.
Sensitivity to RB0
To identify important parameters that affect RB0 , we performed sensitivity analysis
by calculating the sensitivity indices [12]. The sensitivity index of R10 (for the wild-type
virus) and R20 (for the mutant virus) with respect to a parameter x , is given by ∂R
1
0
∂x × xR10
and
∂R20
∂x × xR20 . The negative (or positive) sign of the sensitivity index indicates whether the
wild-type or mutant reproduction number decreases (or increases) when the corresponding
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parameter is increased. From the calculated sensitivity indices (Figures 17 and 18), we
observe that the most sensitive parameters are λ , p1 , and δ1 (for wild-type) and λ , p2 ,
and δ2 (for mutant). We note that while Figures 17 and 18 suggest that λ , p1 , δ1 , p2 ,
and δ2 have the largest impact on the basic reproduction number, the parameters βh1 , c1 ,
σ1 , βh2 , c2 , and σ2 also have significant impact on RB0 . Therefore, the effect of these
parameters can not be entirely ignored while developing HIV control strategies. From our
sensitivity analysis, we observed that neither d , f nor A seem to play a significant role in
the reproduction number.
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Figure 17. Sensitivity of parameters to R10 (wild-type virus).
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Figure 18. Sensitivity of parameters to R20 (mutant virus).
Based on our sensitivity analysis we note that p1 , δ1 , p2 , and δ2 are important for
RB0 . We now identify the regions in the space of these parameters where the wild-type or
the mutant virus is dominant.
67
(a) (b)
0 0.5 1 1.5 2 2.5
0
0.2
0.4
0.6
0.8
1

2
p
1
 (

 1
0
5
)
Wild-type virus dominating region
Mutant virus dominating region
R
0
B >1
	                  
	R
0
B <1
Presence of morphine
Base case
(R
0
B=2.85)
0 0.5 1 1.5 2 2.5
0
0.2
0.4
0.6
0.8
1

2
p
1
 (

 1
0
5
)
Wild-type virus dominating region
Mutant virus dominating region
Base case
(R
0
B=2.25)
	                  
	   R
0
B <1
R
0
B >1
Absence of morphine
Figure 19. Contour plots showing how the basic reproduction number depends on
p1 , the production rate of wild-type virus and δ2 , the death rate of cells infected by
the mutant virus, (a) in the presence of morphine and (b) in the absence of morphine.
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Figure 20. Contour plots showing how the basic reproduction number depends on
p2 , the production rate of mutant virus and δ1 , the death rate of cells infected by the
wild-type virus, (a) in the presence of morphine and (b) in the absence of morphine.
As shown in Figures 19 and 20, the p1δ2 and p2δ1 -parameter spaces are divided by
the curves p1 = f(δ2) and p2 = f(δ1), respectively. Above or below these curves either
the wild-type virus or the mutant virus dominates. As shown in Figure 19, an increase in
δ2 in the mutant virus dominating region and/or a decrease in the p1 in wild-type virus
dominating region decreases the value of RB0 eventually reaching the region where RB0 < 1.
Similarly, in Figure 20, an increase in δ1 in the wild-type virus dominating region and/or a
decrease in the p2 in mutant virus dominating region decreases the value of RB0 eventually
reaching the region where RB0 < 1.
In our study, we find that (in the presence of morphine) if p1 < 17500 and δ2 > 1.58,
or p2 < 21900 and δ1 > 1.97, then RB0 < 1 (Figures 19 (a) and 20 (a)). On the other
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hand, in the absence of morphine, we find that if p1 < 22200 and δ2 > 1.53, or p2 < 22500
and δ1 > 1.55, then RB0 < 1 (Figures 19 (b) and 20 (b)).
Table 6. Model (5.1) parameter values and their interpretations.
Description Parameter Estimate Reference
Reproduction rate of T cells λ 3510 ml−1day−1 [87]
Infection rate of Tl by V1 βl1 5.72 × 10−10 day−1 Estimate, [87]
Infection rate of Th by V1 βh1 5.72 × 10−9 day−1 Estimate, [87]
Infection rate of Tl by V2 βl2 (1 − α)βl1 day−1 Calculated
Infection rate of Th by V2 βh2 (1 − α)βh1 day−1 Calculated
Fitness cost α 0.2 [0-1] Varied
Death rate of T cells d 0.01 day−1 [75, 52]
Death rate of I1 δ1 0.69 day
−1 [87]
Death rate of I2 δ2 0.69 day
−1 [87]
Production rate of V1 p1 5 × 104 day−1 [11, 87]
Production rate of V2 p2 5 × 104 day−1 [11, 87]
Clearance rate of V1 c1 23 day
−1 [66]
Clearance rate of V2 c2 23 day
−1 [66]
Transition rate from Tl to Th r 0.16 day
−1 [87]
Transition rate from Th to Tl q 0.24 day
−1 [87]
Net A(t) effect on infection η 1.1 × 10−5 ml ng−1 Assumed
Net A(t) effect on clearance of V1 σ1 2.5 × 10−3 day−1 Assumed
Net A(t) effect on clearance of V2 σ2 ψσ1 day
−1 Assumed
Escape ratio ψ 0.1[0 − 1] Varied
Morphine concentration M [0 − 400] ng ml−1 Varied
Morphine parameters affecting mutation rate (f) k 3 × 10−5 [82]
µ 0.167 Assumed
γ 0.1 Assumed
Initial number of T cells Tl0 T (0) − Th0 [87]
Th0 40980 [87]
Initial number of infected cells I10 0 [85]
I20 0 [85]
Initial number of Virus V10 200 [46, 85]
V20 40 [0-200] Varied
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Numerical simulation results
Using the parameter values presented in Table 6, we solved our model (5.1) over a
period of 500 days and plotted the individual viral loads (V1 and V2 ), the total viral load
(V1 +V2 ), the ratio of the wild-type and the mutant viral loads (V1/V2 ), and the percentage
of the wild-type in the total viral load (% of V1 =
V1
V1+V2
× 100). We also plotted the CD4
count. For these plots, we varied the fitness cost (α) from 0% to 100%, corresponding to 0
to 1 in the model. Similarly, the escape ratio was varied from 0 to 1.
Effect of fitness cost (α)
We studied the effects of the fitness cost of the mutant virus on the HIV dynamics
by varying the parameter α for the cases of the presence of morphine and the absence of
morphine (Figure 21). Our results show no effect of the fitness cost on V1 , V1 +V2 , and on
the CD4 count in the presence of morphine, whereas in the absence of morphine, increasing
the fitness cost results in an increase in the V1 and in the CD4 count before leveling for a
higher fitness cost (Figure 21). This may be attributed to a successful immune responses
escape by the mutant virus for a lower fitness cost. Then as the immune responses conform
to recognize the mutants, the virus mutation is suppressed thereby allowing more replication
of the wild-type virus. Furthermore, our results show that in the presence and in the absence
of morphine, increasing the fitness cost decreases the V2 , and increases the ratio V1/V2 .
From the results we see almost no difference on the percentage of V1 in the presence and
in the absence of morphine (Figure 21) for a higher fitness cost.
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Figure 21. Effects of fitness cost (α) on HIV dynamics.
Effect of escape ratio (ψ )
Here, we studied the effects of the escape ratio by varying the parameter ψ for the
presence of morphine and the absence of morphine cases (Figure 22). Our results show no
effect of the escape ratio on the V1 , V1+V2 , and on the CD4 count in the presence and in the
absence of morphine. However, we observe slightly higher viral load in V1 and V1 +V2 , and
lower CD4 count in the presence of morphine (Figure 22) than in the absence of morphine.
Also, we see that as the escape ratio increases, V2 decreases with about 2.2 log 10 in the
absence of morphine, whereas in the presence of morphine the V2 remains constant at a
higher value. Moreover, an increase in escape ratio results in a higher, but constant, V1/V2
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in the presence of morphine compared to in the absence of morphine which shows a gradual
increase in V1/V2 . Our results show almost no difference on the percentage of V1 in the
presence and in the absence of morphine (Figure 22).
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Figure 22. Effects of escape ratio (ψ ) on HIV dynamics.
CHAPTER 6
CONCLUSIONS AND DISCUSSION
HIV remains a major public health challenge and one of the highest causes of death
worldwide, with a rapidly increasing dependency on drugs of abuse, such as opiates, in HIV-
infected patients [28, 71, 92]. While drugs of abuse are known to affect the HIV specific
antibody responses [38], how these alterations in antibody response impact within-host
HIV dynamics is not well understood. Therefore, studying the effect of drugs of abuse
on antibody responses and consequently on viral dynamics is of great importance. In this
dissertation, the models we develop extend from a previous mathematical model of SIV
dynamics under morphine conditioning [87].
The model we developed in chapter 3 incorporated the effects of morphine-altered
antibody responses. A previous study that focused on viral dynamics for the first 3 months
post infection [87] did not find any role of immune responses in virus dynamics, consistent
with the low HIV-specific antibody levels during this period (Figure 6). However, we studied
viral dynamics for a longer period of time (i.e., 200 days, Figure 7) and found that the effect
of morphine-altered antibody responses becomes significant enough to alter long-term viral
dynamics. Using our model and the data from SIV/SHIV infected rhesus macaques with
and without morphine conditioning, we determined that the maximum antibody level (a),
the time when the antibody level becomes half-maximal (b), and the Hill coefficient (n)
(slope of the time-response curve) are significantly lower in the rapid-progressor morphine
group than in the control group (Table 1, Figure 6).
Furthermore, excluding animal 1/52N, which has unusually high antibody levels
and high CD4 count, and using a two sample t-test with equal but unknown variances,
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these quantities also become significantly different between the rapid-progressor group and
the slow-progressor group. While the precise mechanism by which morphine alters virus-
specific antibody responses remains to be determined, our results show that morphine has a
significant effect on altering antibody responses, with a tendency to decrease virus-specific
antibody levels and to cause a delay in the time to reach half-maximal antibody responses.
Using these trends of the antibody response, our models further identified that the long
term (200 days post infection) viral dynamics is best described by a model that includes
two immune response effects: reduction of the cell infection rate and an increase in the virus
clearance rate (Table 2). Our models did not support the third effect considered, namely,
antibody-dependent infected cell killing.
Using the best supported model, we quantified the effect of morphine-altered anti-
body responses on the virus infection rate and the virus clearance rate for 200 days post-
infection (Figure 8). Our results show that the efficacy of antibody responses on reducing
virus infection is significantly less in the morphine-dependent animals when compared to
the control group (Figure 8). Similarly, morphine dependence leads to less enhanced virus
clearance in the slow-progressor morphine group and in the rapid-progressor morphine group
than the control group (Figure 8). A higher virus infection rate and/or a lower virus clear-
ance rate in the morphine-dependent animals results in a higher viral load (Figure 7).
The dynamics predicted by the model also shows that CD4 count decreases faster in the
morphine-dependent groups than in the control group. Thus, there is a higher CD4 drop
in the presence of morphine (Figure 9). Although this difference in CD4 drop was not
statistically significant (p > 0.05), our results suggest that there are noticeable effects of
morphine-altered virus-specific antibody responses on CD4 count and that morphine may
exacerbate the disease progression.
We also computed the basic reproduction number, R0 , as 6.48, 2.12, and 1.55 for
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the rapid-progressor morphine, the slow-progressor morphine, and the control groups, re-
spectively, consistent with the observation that the infection got established in each group
(R0 > 1). The higher value of R0 and the lower level of viral-specific antibody response
in the rapid-progressor morphine group imply that morphine can make pre-infection inter-
vention strategies, such as antibody-based vaccines and PrEP, less effective.
To understand the effects of periodic morphine intake, we developed a phamarcody-
namic morphine model that incorporated time-varying efficacy of virus-specific antibodies in
chapter 4. In the model, we considered two cases of morphine pharmacodynamics, namely,
intravenous morphine (IVM) and slow release oral morphine (SROM). In intravenous mor-
phine, the direct administration of morphine into the circulation provides a rapid effect [50].
On the other hand, slow-release oral morphine can be used as pharmacotherapy mainte-
nance treatment for opioid-dependent individuals [7, 23, 26, 27, 31, 36, 51, 90]. Using our
pharmacodynamic morphine model, along with functions that describe morphine dynamics
for IVM and SROM cases, we formulate the infection threshold Ri , that provides a condi-
tion for global stability of infection free equilibrium. We predict that the infection dies out
if Ri < 1 (Theorem 4.3). We determined that the HIV-infection dynamics largely depend
on the pharmacodynamic parameters in both IVM and SROM cases.
In the IVM case, we sought to understand the effects of morphine dose (a0 ) and
the half-life (t1/2 ) on the viral dynamics. Our results show that increasing the morphine
dose, and the half-life increases the infection threshold (Figure 12) as well as the viral load
(Figure 13). Similarly, increasing these pharmacodynamic parameters decreases the CD4
count (Figure 13).
For the SROM case, the pharmacodynamic parameters we considered to study the
HIV-infection dynamics were the mean level of morphine (M0 ) and the morphine amplitude
(a). From our results we observe that increasing the mean level of morphine increases the
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infection threshold and the viral load, and decreases the CD4 count. Furthermore, our
results show that increasing the amplitude decreases the infection threshold (Figure 14), as
well as the viral load (Figure 15). However, an increase in amplitude increases the CD4
count (Figure 15).
We also studied the influence of morphine intake interval on the infection threshold.
We observed that the infection threshold in both IVM and SROM cases grows as the intake
interval decreases (Figures 12 and 14). It is worth noting that, in both the IVM and SROM
cases, the infection threshold is greater than one (i.e., Ri > 1), suggesting the infection
remains persistent (Figures 12 and 14).
Experimental studies have shown that the use of drugs of abuse such as morphine
can affect the mutation rate in macaques [70]. Our model of two viral species we developed
in chapter 5 helps in understanding the interplay of morphine and immune responses escape,
and the fitness cost on HIV dynamics. We derived the basic reproduction number for the
viral dynamics model as RB0 = max
{R10,R20} , where R10 and R20 are the reproduction
numbers for the wild-type virus and mutant virus, respectively. For our model, we computed
RB0 = 2.25 (in the absence of morphine) and RB0 = 2.85 (in the presence of morphine).
Using our model, we studied the effects of the fitness cost and the mutant escape ratio on
various aspects of HIV dynamics (Figures 21 and 22). Our results suggest that the escape
ratio plays no role in altering the dynamics of the wild-type virus. Furthermore, our study
shows that whether or not morphine is present, the wild-type virus dominates.
We acknowledge the several limitations of our study. A limited data set has been
used to estimate parameters in chapter 3. Therefore, some of the numerical estimates
may not be certain. More data from experimental studies including morphine conditioning
and immune responses are needed to obtain more precise parameter estimates and related
results. We considered only antibody responses in our model. However, other immune
77
responses such as those involving CD8+ cells or NK cells might have some effects on the
viral dynamics. Experimental studies involving periodic morphine conditioning could help
more accurately estimate the pharmacodynamic parameters which we observed play an
important role in HIV-infection dynamics.
Future goals stemming from this dissertation include the need to develop and analyze
a model that incorporates a time-varying morphine concentration to study the HIV-infection
dynamics in two viral species. Also, additional work is needed to conduct the analysis to
establish that infection persists (i.e., global analysis for Ri > 1 case) for the morphine
pharmacodynamics model discussed in chapter 4. Other areas which could be of interest
include: development of a model that can help in understanding the effects of morphine on
HIV-infection dynamics in multiple viral species, formulation of optimal control problems
related to the models discussed in this study, as well as conducting a study that incorporates
both the effects of virus-specific antibody responses and CTLs to understand the HIV
dynamics under morphine conditioning.
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